Treatment Strategy for Patients with Relapsed Small-cell Lung Cancer: Past, Present and Future

Overview

Journal Transl Lung Cancer Res

Date 2020 May 19

PMID 32420056

Citations 1

Authors

Kazushige Wakuda

Affiliations

Soon will be listed here.

Citing Articles

Influencing factors of efficacy and long-term use of amrubicin in patients with small cell lung cancer.

Takahara Y, Tanaka T, Ishige Y, Shionoya I, Yamamura K, Sakuma T Thorac Cancer. 2023; 14(14):1286-1293.

PMID: 36994539 PMC: 10175028. DOI: 10.1111/1759-7714.14871.

References

Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S . CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1992; 10(8):1225-9. DOI: 10.1200/JCO.1992.10.8.1225. View

Rudin C, Hann C, Garon E, Ribeiro de Oliveira M, Bonomi P, Camidge D . Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012; 18(11):3163-9. PMC: 3715059. DOI: 10.1158/1078-0432.CCR-11-3090. View

Naka N, Kawahara M, Okishio K, Hosoe S, Ogawara M, Atagi S . Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer. Lung Cancer. 2002; 37(3):319-23. DOI: 10.1016/s0169-5002(02)00073-9. View

Chiappori A, Otterson G, Dowlati A, Traynor A, Horn L, Owonikoko T . A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer. Oncologist. 2016; 21(10):1163-1164. PMC: 5061534. DOI: 10.1634/theoncologist.2016-0220. View

Spigel D, Waterhouse D, Lane S, Legenne P, Bhatt K . Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study. Clin Lung Cancer. 2013; 14(4):356-63. DOI: 10.1016/j.cllc.2012.12.003. View

Ohyanagi F, Horiike A, Okano Y, Satoh Y, Okumura S, Ishikawa Y . Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer. Cancer Chemother Pharmacol. 2007; 61(3):503-8. DOI: 10.1007/s00280-007-0496-6. View

Farago A, Yeap B, Stanzione M, Hung Y, Heist R, Marcoux J . Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. Cancer Discov. 2019; 9(10):1372-1387. PMC: 7319046. DOI: 10.1158/2159-8290.CD-19-0582. View

Pietanza M, Kadota K, Huberman K, Sima C, Fiore J, Sumner D . Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res. 2012; 18(4):1138-45. DOI: 10.1158/1078-0432.CCR-11-2059. View

Zauderer M, Drilon A, Kadota K, Huberman K, Sima C, Bergagnini I . Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. Lung Cancer. 2014; 86(2):237-40. PMC: 4497567. DOI: 10.1016/j.lungcan.2014.08.007. View

10.

Horn L, Mansfield A, Szczesna A, Havel L, Krzakowski M, Hochmair M . First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018; 379(23):2220-2229. DOI: 10.1056/NEJMoa1809064. View

11.

Ando M, Kobayashi K, Yoshimura A, Kurimoto F, Seike M, Nara M . Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer. Lung Cancer. 2004; 44(1):121-7. DOI: 10.1016/j.lungcan.2003.10.003. View

12.

Takeda K, Negoro S, Sawa T, Nakagawa K, Kawahara M, Isobe T . A phase II study of topotecan in patients with relapsed small-cell lung cancer. Clin Lung Cancer. 2003; 4(4):224-8. DOI: 10.3816/clc.2003.n.002. View

13.

Kalemkerian G, Loo B, Akerley W, Attia A, Bassetti M, Boumber Y . NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. J Natl Compr Canc Netw. 2018; 16(10):1171-1182. DOI: 10.6004/jnccn.2018.0079. View

14.

Rouleau M, Patel A, Hendzel M, Kaufmann S, Poirier G . PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010; 10(4):293-301. PMC: 2910902. DOI: 10.1038/nrc2812. View

15.

Byers L, Wang J, Nilsson M, Fujimoto J, Saintigny P, Yordy J . Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012; 2(9):798-811. PMC: 3567922. DOI: 10.1158/2159-8290.CD-12-0112. View

16.

Lammers P, Shyr Y, Li C, Hutchison A, Sandler A, Carbone D . Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer. J Thorac Oncol. 2014; 9(4):559-62. PMC: 3990869. DOI: 10.1097/JTO.0000000000000079. View

17.

OBrien M, Ciuleanu T, Tsekov H, Shparyk Y, Cucevia B, Juhasz G . Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006; 24(34):5441-7. DOI: 10.1200/JCO.2006.06.5821. View

18.

Ettinger D, Jotte R, Lorigan P, Gupta V, Garbo L, Alemany C . Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol. 2010; 28(15):2598-603. DOI: 10.1200/JCO.2009.26.7682. View

19.

Goto K, Ohe Y, Shibata T, Seto T, Takahashi T, Nakagawa K . Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2016; 17(8):1147-1157. DOI: 10.1016/S1470-2045(16)30104-8. View

20.

Han J, Kim H, Lim K, Hwangbo B, Lee J . A phase II study of nintedanib in patients with relapsed small cell lung cancer. Lung Cancer. 2016; 96:108-12. DOI: 10.1016/j.lungcan.2016.04.002. View